Enhancement of tissue plasminogen activator-induced fibrinolysis by activated protein C in endotoxin-treated rabbits
- PMID: 1744501
Enhancement of tissue plasminogen activator-induced fibrinolysis by activated protein C in endotoxin-treated rabbits
Abstract
Endotoxin-treated rabbits produce high levels of plasminogen activator inhibitor-1 (PAI-1), which inhibits fibrinolysis by neutralizing endogenous tissue-type plasminogen activator (t-PA). These animals will develop renal fibrin deposition when infused with ancrod, an enzyme that acts directly on fibrinogen. In normal rabbits with an intact fibrinolytic system, ancrod induces hypofibrinogenemia without fibrin deposition. Rabbit PAI-1 activity can be neutralized by recombinant human t-PA or by bovine activated protein C. The present study determined the efficacy of these two agents used alone or in combination in neutralizing increased PAI-1 activity and in preventing renal fibrin deposition in a rabbit model. Male New Zealand rabbits first received intravenous endotoxin to increase PAI-1 activity. Ancrod was infused intravenously during hour 4 to 5, and the kidneys were examined at hour 5.5. Renal fibrin deposition occurred in 100% (6 out of 6) of the endotoxin-treated rabbits that received ancrod; this was reduced to 14% (1 out of 7) for rabbits receiving t-PA (170 micrograms/kg) before and during the ancrod infusion. Fibrin deposition occurred in only 12% (1 out of 8) of the rabbits that received a 10-fold lower dose of t-PA (17 micrograms/kg) combined with activated protein C (1 mg/kg) before and during the ancrod. Activated protein C at this dose completely neutralized plasma PAI-1 activity. However, low-dose t-PA and activated protein C did not prevent fibrin deposition when used as single agents, with fibrin deposition occurring in 75% and 100% of rabbits, respectively. The data indicate that activated protein C can neutralize plasma PAI-1 activity in vivo.(ABSTRACT TRUNCATED AT 250 WORDS)
Comment in
-
Treatment of thrombosis associated with septic shock.J Lab Clin Med. 1991 Dec;118(6):513-4. J Lab Clin Med. 1991. PMID: 1744500 No abstract available.
Similar articles
-
Plasminogen activator inhibitor: a regulator of ancrod-induced fibrin deposition in rabbits.Blood. 1987 Mar;69(3):798-803. Blood. 1987. PMID: 3101764
-
Endotoxin-induced intravascular coagulation in rabbits: effect of tissue plasminogen activator vs urokinase of PAI generation, fibrin deposits and mortality.Thromb Haemost. 1995 Dec;74(6):1578-82. Thromb Haemost. 1995. PMID: 8772240
-
Effect of plasminogen activator inhibitor-1 on tissue-type plasminogen activator-induced fibrinolysis.Thromb Haemost. 1992 Jan 23;67(1):106-10. Thromb Haemost. 1992. PMID: 1615464
-
Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.Dan Med Bull. 1993 Sep;40(4):383-408. Dan Med Bull. 1993. PMID: 8222763 Review.
-
Fibrin-specific thrombolytic agents.Klin Wochenschr. 1988;66 Suppl 12:15-23. Klin Wochenschr. 1988. PMID: 3126344 Review.
Cited by
-
Perspectives for the future.Intensive Care Med. 1993;19 Suppl 1:S29-34. doi: 10.1007/BF01738947. Intensive Care Med. 1993. PMID: 8227736 Review.
-
Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation.J Clin Invest. 1998 Feb 1;101(3):667-76. doi: 10.1172/JCI575. J Clin Invest. 1998. PMID: 9449701 Free PMC article.
-
Microcirculatory alterations in ischemia-reperfusion injury and sepsis: effects of activated protein C and thrombin inhibition.Crit Care. 2005;9 Suppl 4(Suppl 4):S33-7. doi: 10.1186/cc3758. Epub 2005 Aug 25. Crit Care. 2005. PMID: 16168073 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous